Lupin launches generic oral contraceptive tablets in US
DSIJ IntelligenceCategories: Markets, Trending



Pharma major, Lupin launched Tydemy Tablets (Drospirenone, Ethinyl Estradiol, Levomefolate Calcium and Levomefolate Calcium in the US market.
Pharma major, Lupin launched Tydemy Tablets (Drospirenone, Ethinyl Estradiol, Levomefolate Calcium and Levomefolate Calcium in the US market.
The tablet is the generic equivalent of Safyral manufactured by Bayer HealthCare Pharmaceuticals. The company's drug
The drug Drospirenone-3mg, Ethinyl Estradiol-0.03mg, Levomefolate Calcium-0.451mg and Levomefolate Calcium-0.451mg had an annual sales of US$ 22 million in the US, as per IQVIA data for January 2018.
Lupin is a global pharma developing and manufacturing branded and generic drugs, biotechnology products and APIs. The company operates in Anti-Infective, Asthma, Cardiovascular, CNS, Diabetology, GI, NSAID and Paediatric segment.
On Tuesday, the stock of Lupin closed at Rs. 780.85 per share, up by 1.40